ABIONYX Pharma Releases Q3 2025 Business Update

ABIONYX Pharma reported a consolidated revenue of €3.06 million for the third quarter of 2025, mainly driven by its subsidiary IRIS Pharma's contract research activities in ophthalmology. The company, known for its pioneering work in biopharma, continues to invest in the development of innovative therapies for sepsis and rare diseases, although these divisions did not generate revenue this quarter.

As of September 30, 2025, ABIONYX held a cash position of €2.81 million. The firm received notable financial backing under the France 2030 “i-Démo” project, securing €8.7 million to advance sepsis treatments, with €7 million still pending. This extends their financial viability into the second half of 2026. Moreover, strategic partnerships have been formed, notably with IHU Sepsis and SEBIA, to enhance sepsis diagnostics.